Gastric Cancer Radiation Management

On this page

Quick Reference

RxDrug of choiceFluorouracil 425 mg/m²/day IV bolus + leucovorin 20 mg/m²/day on days 1-5, given concurrently with RT weeks 1, 5, and 9 (INT-0116 regimen).

AltAlternativesCapecitabine 825 mg/m² PO BID on days of RT (ARTIST regimen); FOLFOX (oxaliplatin + infusional 5-FU) for definitive CRT.

⊘AvoidActive inflammatory bowel disease, prior abdominal RT exceeding total tolerance, pregnancy, inability to tolerate breath-hold (if needed), R2 resection after D2 dissection (no benefit).

DxTest of choiceContrast-enhanced CT of chest, abdomen, pelvis for staging and planning; 4D CT simulation for motion management.

ScKey scoreLocoregional failure nomogram after D2 surgery: includes pT category (3-4 vs 1-2) and lymph node ratio (>25% vs ≤25%); AUC 0.79.

→When to referRefer to radiation oncology for any patient with resected gastric cancer after D0/D1 dissection, unresectable local disease, or symptomatic bleeding/pain/obstruction. Refer to surgical oncology for anastomotic stricture, pancreatic fistula, or duodenal stump fistula. Refer to palliative care for advanced disease.

Adjuvant chemoradiotherapy (45 Gy + FU/leucovorin) is indicated after D0/D1 R0 resection; after D2 R0 resection, RT does not improve outcomes. For unresectable disease, definitive CRT (50.4 Gy) or palliative RT (30 Gy/10 fx) provides effective symptom control. IMRT with breath-hold techniques reduces toxicity.

Radiation management for [[gastric cancer]] spans curative-intent adjuvant treatment to palliation. Indications depend on surgery extent, nodal dissection, and chemotherapy. Key trials include INT-0116, ARTIST, CRITICS, and TOPGEAR. Modern techniques use IMRT/VMAT with careful OAR sparing. Brachytherapy offers salvage for limited metastases. Concurrent chemoradiation with fluoropyrimidine is standard after suboptimal dissection.

Overview and Recommendations

Background

•Radiation therapy (RT) for gastric cancer targets locoregional control, addressing the dominant failure pattern after limited nodal dissection. The landmark INT-0116 trial (1998) established postoperative chemoradiotherapy (45 Gy with concurrent fluorouracil and leucovorin) as a standard after R0 resection with D0/D1 lymphadenectomy, reducing locoregional relapse and improving overall survival (HR 1.32).
•The benefit of adjuvant RT is context-dependent: after adequate D2 gastrectomy, the addition of radiotherapy to modern chemotherapy (e.g., SOX) does not improve disease-free survival (ARTIST 2). Subgroup analyses suggest possible benefit in node-positive, intestinal-type tumors, but routine use is not recommended.
•For patients with locally advanced, unresectable gastric cancer, definitive chemoradiotherapy (45-50.4 Gy) provides durable disease control, with clinical complete response rates of 12-45% and median overall survival of 11-26 months. Palliative RT (30 Gy/10 fx) effectively controls bleeding (60-90%), pain (45-100%), and obstruction (53-100%) with <5% grade 3 GI toxicity.
•Preoperative chemoradiotherapy increases pathological complete response (pCR) rates (17% vs 8% in TOPGEAR) but does not improve overall survival compared to perioperative chemotherapy alone. It is conditionally recommended for borderline resectable tumors or patients who cannot tolerate perioperative chemotherapy.
•Brachytherapy (interstitial HDR or permanent 125I seeds) offers a minimally invasive option for limited-volume metastases (<3 cm, PTV <45 cm³) or locoregional recurrence after gastrectomy, achieving local control of 89% and 50% complete response, respectively, with low toxicity.
•The paradigm shift from 3D-CRT to IMRT/VMAT, combined with breath-hold techniques and daily IGRT, has improved target coverage and reduced toxicity to kidneys, liver, and bowel. Renal function is a key concern, with left kidney dose constraints (mean ≤13 Gy, V20 ≤13%) critical to prevent functional impairment.

Evaluation

•Suspect the need for gastric cancer RT in any patient with resected stage IB-III disease after D0/D1 lymphadenectomy, unresectable local disease, or symptomatic bleeding/pain/obstruction from advanced disease.
•Review the operative report to determine the extent of lymph node dissection (D0/D1 vs D2) and margin status (R0/R1/R2), this is the single most important factor guiding RT indication.
•Assess patient fitness for concurrent chemotherapy: ECOG performance status 0-2, adequate renal function (eGFR ≥30 mL/min), hepatic function, and marrow reserve (ANC ≥1.5, platelets ≥100).
•Obtain a baseline contrast-enhanced CT of the chest, abdomen, and pelvis for staging and treatment planning. PET/CT may be considered for detection of occult metastases, especially in the preoperative setting.
•For adjuvant RT after D2 dissection, identify high-risk features: pT3-4, lymph node ratio >25%, or extraperigastric nodal involvement. A nomogram (AUC 0.79) can predict locoregional failure risk and guide patient selection.
•For definitive RT, perform endoscopic ultrasound (EUS) for T and N staging, and rule out distant metastases with imaging. Consider diagnostic laparoscopy to exclude peritoneal dissemination before high-dose RT.
•For palliative RT, document the target symptom (bleeding, pain, obstruction) and its severity. For bleeding, confirm active bleeding source via endoscopy and consider prior embolization if RT is not immediately available.
•Assess prior radiation exposure: if the patient has received previous abdominal RT, obtain treatment records and calculate cumulative dose to OARs, especially kidneys, spinal cord, and bowel.
•Evaluate for contraindications: active inflammatory bowel disease, pregnancy, prior radiation to the same field exceeding tolerance, or inability to tolerate immobilization (e.g., breath-hold).
•Obtain a 4D CT simulation with the patient in supine position, arms up, with a custom immobilization device. Use oral contrast to delineate the stomach body and tumor bed. Consider breath-hold planning if respiratory motion >1 cm in the SI direction.

Management

•For adjuvant RT after D0/D1 R0 resection: prescribe 45 Gy in 25 fractions (1.8 Gy/fx) to the tumor bed, anastomosis, duodenal stump, and regional lymph nodes (perigastric stations 1-6, celiac 9, splenic 10-11, hepatoduodenal 12, pancreaticoduodenal 13, para-aortic 16).
•Deliver concurrent chemotherapy: fluorouracil 425 mg/m²/day IV bolus on days 1-5 and leucovorin 20 mg/m²/day IV bolus on days 1-5, repeated at weeks 1, 5, and 9 (INT-0116 regimen). Alternatively, capecitabine 825 mg/m² PO BID on days of RT (ARTIST regimen).
•After D2 R0 resection, do not routinely add RT to adjuvant chemotherapy. For patients with high-risk features (pT3-4, N2+, extraperigastric LN), consider a shared decision-making discussion; if RT is offered, target the para-aortic basin (stations 16a/16b) and omit perigastric stations 1-6 and splenic hilum.
•For unresectable nonmetastatic disease: prescribe 50.4 Gy in 28 fractions (1.8 Gy/fx) with concurrent fluoropyrimidine (e.g., capecitabine 825 mg/m² BID) or FOLFOX. Consider induction chemotherapy (2 cycles of SOX or FOLFOX) before CRT.
•For palliative RT for bleeding: prescribe 30 Gy in 10 fractions (3 Gy/fx). Symptom relief typically occurs within 2-10 days. For pain or obstruction, the same regimen is effective; for obstruction, consider a higher dose (39 Gy in 13 fx or 40 Gy in 20 fx) if tolerance permits.
•Use IMRT or VMAT preferentially to reduce dose to kidneys, liver, and bowel. Key OAR constraints: liver mean ≤16 Gy, V30 ≤21%; right kidney mean ≤9 Gy, V20 ≤9%; left kidney mean ≤13 Gy, V20 ≤13%; heart V40 ≤17%; bowel mean ≤11 Gy, V40 ≤6%; spinal cord max ≤33 Gy.
•Implement respiratory motion management: use 4D CT simulation to define the ITV. If breath-hold is feasible, use deep inspiration breath-hold (DIBH) to reduce SI motion to ~2 mm, allowing margin reduction and potential dose escalation to 54 Gy.
•For patients with preexisting nephropathy (eGFR <60 mL/min), prioritize IMRT/VMAT and consider referral to a center with proton therapy to further reduce renal dose.
•Monitor during treatment: weekly CBC, CMP, and symptom assessment. Grade 3 GI toxicity (nausea, vomiting, diarrhea) occurs in 0-31% of definitive cases; manage with antiemetics (ondansetron 8 mg PO TID, prochlorperazine 10 mg PO QID), loperamide, and IV fluids as needed.
•Do not use multiagent concurrent chemotherapy (e.g., ECF), CALGB 80101 showed no survival benefit over single-agent fluoropyrimidine.
•Do not add postoperative RT after preoperative chemotherapy and D2 surgery (CRITICS trial showed harm, HR 1.62).
•For brachytherapy candidates: select patients with ≤5 metastases, each <3 cm, PTV <45 cm³, and good performance status. For liver metastases, use image-guided HDR interstitial brachytherapy (single fraction, 15-20 Gy). For locoregional recurrence, use CT-guided 125I seed implantation (100-160 Gy minimal peripheral dose).
•After RT, monitor for late toxicity: anastomotic stricture (5.9%), dysphagia (28.3% with right esophagojejunostomy, 12.5% with left), and pancreatic fistula. Refer to surgical oncology for management of strictures (endoscopic dilation) and nutritional support if needed.
•Refer to palliative care early for symptom management and advanced care planning, especially for patients with inoperable disease. Early integration reduces emergency visits and hospitalizations.
•Discharge criteria from RT: completion of prescribed course, stable vital signs, adequate oral intake, controlled pain, and no evidence of acute grade ≥3 toxicity. Follow up in 4-6 weeks with imaging and symptom assessment.

Board Review — High Yield

•INT-0116, Landmark trial establishing adjuvant chemoradiotherapy (45 Gy + FU/leucovorin) after D0/D1 R0 resection for T3-4 or N+ gastric cancer; HR for OS 1.32, HR for RFS 1.51.
•ARTIST 2, After D2 resection, adding RT to SOX does not improve 3-year DFS compared to SOX alone (72.8% vs 74.3%; HR 0.971); modern chemotherapy alone is sufficient.
•CRITICS trial, After preoperative chemotherapy and D2 surgery, postoperative chemoradiotherapy worsened OS compared to chemotherapy alone (per-protocol 5-year OS 45.5% vs 57.9%; HR 1.62).
•TOPGEAR, Preoperative CRT (45 Gy) increases pCR (17% vs 8%) but does not improve OS over perioperative chemotherapy alone.
•Palliative RT dose, 30 Gy in 10 fractions is the standard for bleeding, pain, and obstruction; response rates: bleeding 60-90%, pain 45-100%, obstruction 53-100%.
•IMRT benefit, Meta-analysis shows IMRT improves 3-year local control over 3D-CRT with no significant difference in OS or toxicity.
•Brachytherapy selection, Lesion size <3 cm and PTV <45 cm³ are critical predictors of complete response; HDR iBT for metastases, 125I seeds for locoregional recurrence.
•Para-aortic station 16, Most common site of locoregional failure after D2 dissection; should be included in CTV for high-risk patients.
•Left kidney dose, Mean ≤13 Gy, V20 ≤13% are critical constraints to prevent functional impairment; use IMRT or breath-hold to achieve.
•CALGB 80101, Multiagent concurrent chemotherapy (ECF) does not improve survival over single-agent FU when combined with RT; use single-agent FU.

Deep Dive — Evidence Details

Indications by Stage

▸Adjuvant chemoradiation after D0/D1 dissection improves OS (INT-0116).
▸No benefit after D2 dissection; definitive chemoradiation for unresectable disease.

HY High Yield: Adjuvant chemoradiation is not recommended after D2, R0 resection [19].

Radiation therapy for is indicated across the disease spectrum. Adjuvant chemoradiotherapy is indicated after suboptimal nodal dissection (D0/D1) based on INT-0116 (45 Gy with concurrent 5-FU/leucovorin, HR for OS 1.32) ^[2]^A1b. After adequate D2 dissection, the ARTIST trial ^[5]^A1b and a Chinese phase III trial ^[19]^A1b showed no DFS benefit, so it is not recommended. Preoperative chemoradiation is conditionally recommended for borderline resectable tumors or when patients cannot tolerate perioperative chemotherapy; TOPGEAR showed no OS benefit but increased pCR (17% vs 8%) ^[11]^B2b. For locally advanced unresectable disease, definitive chemoradiotherapy (45-50.4 Gy) provides durable control (median OS 11-26.4 months) ^[17]^A1a. For palliation, high-dose RT (e.g., 30 Gy/10 fractions) achieves bleeding response rates 60-90% ^[17]^A1a. Pearl: For patients with D2-resected gastric cancer, the addition of radiotherapy to adjuvant chemotherapy does not improve survival; its role is limited to cases of suboptimal nodal dissection (D0/D1) or R1/R2 resection, where it remains a conditionally recommended option.

Key Trials Shaping Indications for Radiotherapy in Gastric Cancer

Trial	Population	Intervention	Key Finding	Implication for Indication
INT-0116 ^[2]^A1b	R0, T3-4/N+, <D2 dissection	Postop CRT vs observation	OS HR 1.32 (95% CI 1.10-1.60)	Postop CRT indicated for <D2
ARTIST ^[3]^A1b^[5]^A1b	D2, R0, all stages	XP vs XPRT	DFS similar; subset benefit in node+	Not routine after D2
CRITICS ^[1]^A1b^[9]^A1b	Preop chemo, D1+ dissection	Postop chemo vs CRT	OS HR 1.01 (95% CI 0.84-1.22)	No benefit for postop CRT after preop chemo
TOPGEAR ^[11]^B2b	Resectable, perioperative chemo	Preop CRT + chemo vs chemo alone	OS HR 1.05 (95% CI 0.83-1.31)	Preop CRT not superior to chemo alone
Chinese D2 trial ^[19]^A1b	D2, T4/N+, R0	SOX vs SOX+RT (50.4 Gy)	3y DFS 70.5% vs 69.3% (HR 0.98)	No benefit for adjuvant RT after D2
Definitive RT ^[17]^A1a	Inoperable, nonmetastatic	45-50.4 Gy/25-28# with chemo	mOS 11-26.4 mo, cCR 12-45%	Definitive CRT offers durable control
Palliative RT ^[17]^A1a	Advanced/metastatic	30 Gy/10# (most common)	Bleeding RR 60-90%, pain RR 46-100%	Effective palliation for bleeding, pain, obstruction

Brachytherapy

▸Brachytherapy for oligometastases: local control 89% with iBT.
▸Permanent seeds for local recurrence: 50% CR, median OS 22 mo.

HY High Yield: Lesion size <3 cm and PTV <45 cm³ are critical predictors of success [47].

Brachytherapy is used for salvage or palliation of limited metastases or locoregional recurrence. Image-guided HDR interstitial brachytherapy (iBT) for hepatic, lymphatic, or pancreatic metastases: single-fraction Ir-192 achieved local control in 89% of 36 lesions, median PFS 6.6 months, OS 11.4 months ^[43]^C4. CT-guided permanent brachytherapy (125I seeds) for locoregional recurrence: 50% complete response, median survival 22 months ^[47]^D5. Predictors of response: tumor size <3 cm and PTV <45 cm³. Preclinical evidence shows 125I seeds induce apoptosis and inhibit NF-κB/VEGF ^[48]^D5. Optimal candidates: solitary/oligometastatic (≤5 lesions), size <3 cm, favorable PS. Low toxicity (grade ≥3 <3%). Pearl: For selected patients with limited locoregional recurrence or oligometastases from gastric cancer, brachytherapy achieves high local control (89% for metastases, 50% complete response for recurrences) with minimal toxicity, but lesion size <3 cm and PTV <45 cm³ are critical predictors of success ^[43]^C4^[47]^D5.

Outcomes of Brachytherapy for Gastric Cancer

Indication	Technique	Patients (n)	Local Control	Median Survival	Reference
Hepatic, lymphatic, pancreatic metastases	HDR iridium-192 interstitial BT	12 (36 lesions)	89% (32/36)	OS 11.4 mo, PFS 6.6 mo	^[43]^C4
Locoregional recurrence	CT-guided 125I seed permanent BT	28	CR 50%, PR 28.6%	22.0 mo (1-yr 89%, 2-yr 52%)	^[47]^D5

Concurrent Chemoradiation

▸Standard concurrent agent: fluoropyrimidine (5-FU or capecitabine).
▸Multiagent regimens (ECF) do not improve outcomes over single-agent (CALGB 80101).

HY High Yield: After D2 dissection, chemoradiation is not superior to chemotherapy alone (ARTIST, CRITICS).

Concurrent chemoradiation is the cornerstone of adjuvant treatment after suboptimal dissection. INT-0116 used 45 Gy with bolus 5-FU/leucovorin, improving OS (HR 1.32) and RFS (HR 1.51) ^[2]^A1b. ARTIST after D2 dissection showed no DFS benefit overall, but subset analysis favored node-positive intestinal-type ^[3]^A1b. CALGB 80101 found no benefit of multiagent ECF over single-agent FU with RT (5-year OS 44% both) ^[4]^A1b. CRITICS after preoperative chemo and D2 surgery: postoperative chemoradiation was inferior to chemotherapy alone (5-year OS 57.9% vs 45.5%, adjusted HR 1.62) ^[1]^A1b. Practical: concurrent agent is fluoropyrimidine (IV 5-FU or oral capecitabine). Dose 45 Gy/25 fx. Decision depends on surgery quality and nodal status. Pearl: Multiagent concurrent chemotherapy (ECF) does not improve survival over single-agent fluoropyrimidine when combined with radiation (CALGB 80101).

Landmark Trials of Concurrent Chemoradiation in Gastric Cancer

Trial	Surgery	Arms	RT Dose	Key Result
INT-0116 ^[2]^A1b	D0/D1	Observation vs FU/LV + 45 Gy → FU/LV	45 Gy/25 fx	HR for OS 1.32 (95% CI 1.10-1.60); HR for RFS 1.51 (95% CI 1.25-1.83)
ARTIST ^[3]^A1b	D2	XP ×6 vs XP ×2 → XPRT → XP ×2	45 Gy/25 fx (capecitabine concurrent)	DFS HR 0.740 (95% CI 0.520-1.050); benefit in node-positive and intestinal-type
CALGB 80101 ^[4]^A1b	D0/D1/D2	FU/LV + 45 Gy vs ECF + 45 Gy	45 Gy/25 fx (FU concurrent)	5-yr OS 44% both arms; HR 0.98 (95% CI 0.78-1.24)
CRITICS ^[1]^A1b	D2	Post-op CT vs post-op CRT (after pre-op CT)	45 Gy/25 fx (capecitabine or FU concurrent)	5-yr OS 57.9% CT vs 45.5% CRT; adjusted HR 1.62 (95% CI 1.24-2.12)

Acute and Late Toxicity

▸Cardiotoxicity highest with anti-VEGFR-TKIs (RR 5.62).
▸Pancreas-contactless technique eliminates POPF (0% vs 7.6%).

! Warning: Monitoring for cardiotoxicity mandatory with vandetanib, ramucirumab, aflibercept.

Toxicity from multimodality treatment includes cardiotoxicity from targeted agents (e.g., vandetanib RR 7.71, ramucirumab RR 5.0) ^[83]^B2a. Gastric cancer has 4% incidence of cardiotoxicity. Anti-VEGFR-TKIs carry highest risk (RR 5.62) ^[83]^B2a. Postoperative complications: anastomotic leakage (1.4% with DFT reconstruction) ^[85]^A1a, pancreatic fistula (1.8% DFT) ^[85]^A1a, anastomotic stricture (5.9% DFT) ^[85]^A1a. Prevention: duodenal stump reinforcement reduces DSF (OR 0.32) ^[91]^B2a; pancreas-contactless technique reduces POPF (0% vs 7.6%) ^[95]^B3b; left esophagojejunostomy (LEJ) reduces dysphagia (12.5% vs 28.3%) ^[101]^C4. Management: drainage, antibiotics, endoscopic dilation. Cardiac monitoring recommended for patients on targeted agents. Pearl: Anastomotic stricture and dysphagia are common late complications after total gastrectomy; technique refinements such as left esophagojejunostomy (LEJ) and intracorporeal anastomosis significantly reduce these risks, and the benefit is seen in the first postoperative year ^[92]^B2a^[101]^C4.

Complications of Multimodality Treatment for Gastric Cancer

Complication	Frequency	Prevention	Management
Anastomotic leakage	1.4% (DFT) ^[85]^A1a; 8.3% (surgery-first) ^[97]^C4	Duodenal stump reinforcement (OR 0.32) ^[91]^B2a	Drainage, surgical repair, antibiotics
Pancreatic fistula	1.8% (DFT) ^[85]^A1a; 0% with contactless technique ^[95]^B3b	Pancreas-contactless technique ^[95]^B3b; robotic gastrectomy for Type C LGV ^[94]^C4	Drainage, somatostatin analogs, nutritional support
Anastomotic stricture	5.9% (DFT) ^[85]^A1a; 3.7% EOJ vs 1.8% IOJ ^[92]^B2a	Intracorporeal anastomosis (OR 2.00 for EOJ) ^[92]^B2a; LEJ reduces dysphagia ^[101]^C4	Endoscopic dilation, surgical revision if severe
Cardiotoxicity (targeted agents)	4% in gastric cancer ^[83]^B2a	Baseline cardiac assessment, avoid high-risk agents in susceptible patients	Dose reduction, hold agent, cardiology consultation
Intra-abdominal abscess	3.2% (contactless) vs 12.1% (contact) ^[95]^B3b	Avoid pancreatic trauma, meticulous hemostasis	Drainage, culture-directed antibiotics
Dysphagia	28.3% REJ vs 12.5% LEJ ^[101]^C4	Left esophagojejunostomy (LEJ) technique (OR 0.248) ^[101]^C4	Dietary modification, prokinetics; surgical repositioning for volvulus

Outcomes

▸INT-0116: OS benefit with chemoradiation after D0/D1 dissection.
▸ARTIST 2: no benefit of adding RT to SOX after D2 resection.

HY High Yield: Nodal response to preoperative therapy is more prognostic than primary tumor response (HR 0.54) [104].

INT-0116 (10-year follow-up): postoperative chemoradiation improved OS (HR 1.32) and RFS (HR 1.51) ^[2]^A1b. ARTIST 2 after D2 resection: 3-year DFS 64.8% (S-1), 74.3% (SOX), 72.8% (SOXRT). No significant difference between SOX and SOXRT (HR 0.971) ^[110]^A1b. Preoperative RT: higher nodal response (46% vs 29.1% for cardia, 43.8% vs 31.9% for noncardia) ^[104]^B3b. Nodal downstaging is a strong prognostic factor (HR 0.54) ^[104]^B3b. Controversy: after D2 dissection, modern chemotherapy alone may suffice; RT should be reserved for high-risk features or inadequate lymphadenectomy. Pearl: Nodal response after preoperative therapy is a stronger prognostic marker than primary tumor response, and radiotherapy increases the likelihood of achieving nodal downstaging ^[104]^B3b.

Key Outcomes from Landmark Trials

Trial	Setting	Regimen	Outcome	Effect Size
ARTIST 2 ^[110]^A1b	D2-resected, stage II/III, N+	SOXRT vs SOX vs S-1 alone	3-year DFS: SOX 74.3%, SOXRT 72.8%, S-1 64.8%	SOX vs S-1: HR 0.692 (P = 0.042); SOX vs SOXRT: HR 0.971 (P = 0.879)
Sada et al. ^[104]^B3b	Preoperative cN+	Chemo ± RT	Nodal response rate: 46% (RT) vs 29% (chemo) in cardia	Nodal response with residual primary: HR 0.54 (95% CI 0.44-0.65)

References

[1]
de Steur WO, van Amelsfoort RM, Hartgrink HH et al.. “Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33227408 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
[2]
Smalley SR, Benedetti JK, Haller DG et al.. “Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22585691 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
[3]
Park SH, Sohn TS, Lee J et al.. “Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25559811 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
[4]
Fuchs CS, Niedzwiecki D, Mamon HJ et al.. “Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28976791 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
[5]
Lee J, Lim DH, Kim S et al.. “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22184384 ↗
L1RCTCited in: Indications by Stage
[6]
Sclafani F, Roy A, Cunningham D et al.. “HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24146218 ↗
L2RCT_PHASE2Cited in: Indications by Stage, Concurrent Chemoradiation
[7]
Schwartz GK, Winter K, Minsky BD et al.. “Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19273696 ↗
L2RCT_PHASE2Cited in: Indications by Stage
[8]
Oehler C, Ciernik IF. “Radiation therapy and combined modality treatment of gastrointestinal carcinomas.” Cancer treatment reviews (2006). PMID: 16524667 ↗
L1RCTCited in: Indications by Stage, Adjuvant and Palliative RT
[9]
Cats A, Jansen EPM, van Grieken NCT et al.. “Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29650363 ↗
L1RCTCited in: Indications by Stage
[10]
van Velzen MJM, Pape M, Sprangers MAG et al.. “Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38977016 ↗
L2PROSPECTIVE_COHORTCited in: Indications by Stage
[11]
Leong T, Smithers BM, Michael M et al.. “Preoperative Chemoradiotherapy for Resectable Gastric Cancer.” The New England journal of medicine (2024). PMID: 39282905 ↗
L2RCT_PHASE2Cited in: Indications by Stage
[12]
Gordon MA, Gundacker HM, Benedetti J et al.. “Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23524864 ↗
L2NON_RANDOMIZED_TRIALCited in: Indications by Stage
[13]
Vitolo U, Chiappella A, Ferreri AJ et al.. “First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21646602 ↗
L2NON_RANDOMIZED_TRIALCited in: Indications by Stage
[14]
Ajani JA, Winter K, Okawara GS et al.. “Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16921048 ↗
L2NON_RANDOMIZED_TRIALCited in: Indications by Stage, Adjuvant and Palliative RT
[15]
Anker CJ, Arshad J, Cellini F et al.. “Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.” Practical radiation oncology (2025). PMID: 41317985 ↗
L1GUIDELINECited in: Indications by Stage
[16]
Ma X, Guo W, Sun J et al.. “Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.” Frontiers in immunology (2026). PMID: 42292472 ↗
L1SR_MA_RCTCited in: Indications by Stage
[17]
Case A, Williams F, Prosser S et al.. “Reconsidering the Role of Radiotherapy for Inoperable Gastric Cancer: A Systematic Review of Gastric Radiotherapy Given With Definitive and Palliative Intent.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2024). PMID: 39642760 ↗
L1SR_MA_RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Adjuvant and Palliative RT
[18]
Pera M, Gallego R, Montagut C et al.. “Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21652581 ↗
L4PHASE_1_TRIALCited in: Indications by Stage
[19]
Wang X, Yan O, Zhou J et al.. “Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42295761 ↗
L1RCTCited in: Indications by Stage
[20]
Liu X, Jin J, Zhou M et al.. “Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.” Cancer communications (London, England) (2026). PMID: 41625476 ↗
L1RCTCited in: Indications by Stage
[21]
Qiao XX, Jiang HG, Tang Y et al.. “Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study.” International journal of radiation oncology, biology, physics (2025). PMID: 40185210 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT)
[22]
Chang JS, Koom WS, Lee Y et al.. “Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection?” World journal of gastroenterology (2014). PMID: 25278687 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT)
[23]
Zhu WG, Xua DF, Pu J et al.. “A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2012). PMID: 22985776 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT)
[24]
Yu C, Yu R, Zhu W et al.. “Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery.” Journal of cancer research and clinical oncology (2011). PMID: 22105898 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT)
[25]
Callister MD, Gunderson LL. “Advancements in radiation techniques for gastric cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20410335 ↗
L5OTHERCited in: External Beam Radiotherapy (EBRT)
[26]
Pasquier C, Créhange G, Vendrely V et al.. “Radiotherapy for cancers of the oesophagus, gastroesophageal junction, and stomach.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41205452 ↗
L1GUIDELINECited in: External Beam Radiotherapy (EBRT)
[27]
Créhange G, Huguet F, Quero L et al.. “[Radiotherapy in cancers of the oesophagus, the gastric cardia and the stomach].” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2016). PMID: 27523409 ↗
L1GUIDELINECited in: External Beam Radiotherapy (EBRT), Brachytherapy
[28]
Liu Y, Zhao G, Xu Y et al.. “Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer.” International journal of radiation oncology, biology, physics (2017). PMID: 28721893 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[29]
Wang X, Shen Y, Zhu H et al.. “A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2015). PMID: 25609451 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[30]
Badakhshi H, Gruen A, Graf R et al.. “Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2013). PMID: 24122094 ↗
L4NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[31]
Hu W, Ye J, Wang J et al.. “Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric study.” Radiation oncology (London, England) (2012). PMID: 22716276 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[32]
Alani S, Soyfer V, Strauss N et al.. “Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer.” International journal of radiation oncology, biology, physics (2009). PMID: 19427558 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[33]
Wang X, Li G, Zhang Y et al.. “Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT).” Medical dosimetry : official journal of the American Association of Medical Dosimetrists (2013). PMID: 23791504 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT)
[34]
Haneder S, Budjan JM, Schoenberg SO et al.. “Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer.” Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2014). PMID: 25445156 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[35]
Boda-Heggemann J, Weiss C, Schneider V et al.. “Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.” Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2013). PMID: 23558673 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT)
[36]
Ren F, Li S, Zhang Y et al.. “Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis.” Radiation oncology (London, England) (2019). PMID: 31118042 ↗
L2SR_COHORTCited in: External Beam Radiotherapy (EBRT)
[37]
Wang X, Zhao DB, Yang L et al.. “S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.” British journal of cancer (2017). PMID: 29235569 ↗
L4PHASE_1_TRIALCited in: External Beam Radiotherapy (EBRT)
[38]
Qiu M, Peng XC, Bi F et al.. “Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.” Medical oncology (Northwood, London, England) (2015). PMID: 26025485 ↗
L4PHASE_1_TRIALCited in: External Beam Radiotherapy (EBRT)
[39]
Wang X, Jin J, Li YX et al.. “Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.” World journal of gastroenterology (2014). PMID: 24574780 ↗
L4PHASE_1_TRIALCited in: External Beam Radiotherapy (EBRT)
[40]
Liu D, Ma X, Xiao D et al.. “Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.” Oncotarget (2017). PMID: 29487720 ↗
L2SR_COHORTCited in: Brachytherapy
[41]
Di Vita M, Cappellani A, Piccolo G et al.. “The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows.” Anti-cancer drugs (2015). PMID: 25406023 ↗
L1SR_MA_RCTCited in: Brachytherapy
[42]
Wang J, Xiong J, Wang P et al.. “Analysis of the safety and efficacy of the self-pulling and latter transected technique in modified overlap anastomosis in total laparoscopic total gastrectomy.” Frontiers in oncology (2024). PMID: 38854721 ↗
L4COHORTCited in: Brachytherapy
[43]
Omari J, Drewes R, Orthmer M et al.. “Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy.” Diagnostic and interventional radiology (Ankara, Turkey) (2019). PMID: 31348004 ↗
L4COHORTCited in: Brachytherapy
[44]
Sugarbaker PH. “Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2007). PMID: 17701534 ↗
L2NON_RANDOMIZED_TRIALCited in: Brachytherapy
[45]
Turina M, Pavlik CM, Heinimann K et al.. “Recurrent desmoids determine outcome in patients with Gardner syndrome: a cohort study of three generations of an APC mutation-positive family across 30 years.” International journal of colorectal disease (2012). PMID: 23114473 ↗
L2NON_RANDOMIZED_TRIALCited in: Brachytherapy
[46]
Halpern AL, McCarter MD. “Palliative Management of Gastric and Esophageal Cancer.” The Surgical clinics of North America (2019). PMID: 31047042 ↗
L5NARRATIVE_REVIEWCited in: Brachytherapy
[47]
Shi L, Wu C, Wu J et al.. “Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer.” Radiation oncology (London, England) (2012). PMID: 22827960 ↗
L5OTHERCited in: Brachytherapy
[48]
Zhang WF, Jin WD, Li B et al.. “Effect of brachytherapy on NF-κB and VEGF in gastric carcinoma xenografts.” Oncology reports (2014). PMID: 24926530 ↗
L5OTHERCited in: Brachytherapy
[49]
Zhang Y, Chung Y. “Nonparametric estimation of linear personalized diagnostics rules via efficient grid algorithm.” Statistics in medicine (2024). PMID: 38287456 ↗
L5OTHERCited in: Brachytherapy
[50]
Virgilio E, Ceci D, Cavallini M. “Surgical Endoscopic Vacuum-assisted Closure Therapy (EVAC) in Treating Anastomotic Leakages After Major Resective Surgery of Esophageal and Gastric Cancer.” Anticancer research (2018). PMID: 30275175 ↗
L4CASE_SERIESCited in: Brachytherapy
[51]
Chau I, Norman AR, Cunningham D et al.. “The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19164454 ↗
L1SR_MA_RCTCited in: Concurrent Chemoradiation, Outcomes
[52]
Grenader T, Waddell T, Peckitt C et al.. “Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26787231 ↗
L1RCTCited in: Concurrent Chemoradiation
[53]
Yamada Y, Higuchi K, Nishikawa K et al.. “Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25316259 ↗
L1RCTCited in: Concurrent Chemoradiation
[54]
Ajani JA, Abramov M, Bondarenko I et al.. “A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28911091 ↗
L1RCTCited in: Concurrent Chemoradiation
[55]
Fazio N, Biffi R, Maibach R et al.. “Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712905 ↗
L1RCTCited in: Concurrent Chemoradiation
[56]
Kanagavel D, Pokataev IA, Fedyanin MY et al.. “A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20150573 ↗
L1RCTCited in: Concurrent Chemoradiation
[57]
Ryu MH, Baba E, Lee KH et al.. “Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26216386 ↗
L1RCTCited in: Concurrent Chemoradiation
[58]
Okines AF, Thompson LC, Cunningham D et al.. “Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23233651 ↗
L1RCTCited in: Concurrent Chemoradiation
[59]
Bajetta E, Floriani I, Di Bartolomeo M et al.. “Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24728035 ↗
L1RCTCited in: Concurrent Chemoradiation
[60]
Ishigami H, Fujiwara Y, Fukushima R et al.. “Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29746229 ↗
L1RCTCited in: Concurrent Chemoradiation
[61]
Ohtsu A, Shah MA, Van Cutsem E et al.. “Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21844504 ↗
L1RCTCited in: Concurrent Chemoradiation
[62]
Aoyama T, Nishikawa K, Fujitani K et al.. “Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28486692 ↗
L2RCT_PHASE2Cited in: Concurrent Chemoradiation
[63]
Shah MA, Janjigian YY, Stoller R et al.. “Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26438119 ↗
L2RCT_PHASE2Cited in: Concurrent Chemoradiation
[64]
Shitara K, Bang YJ, Wyrwicz LS et al.. “Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.” ESMO open (2026). PMID: 41747585 ↗
L1RCTCited in: Concurrent Chemoradiation
[65]
Fujitani K, Yang HK, Mizusawa J et al.. “Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.” The Lancet. Oncology (2016). PMID: 26822397 ↗
L1RCTCited in: Concurrent Chemoradiation
[66]
Rosati G, Bilancia D, Germano D et al.. “Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591806 ↗
L2NON_RANDOMIZED_TRIALCited in: Adjuvant and Palliative RT
[67]
Ly QP, Sasson AR. “Modern surgical considerations for gastric cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18926098 ↗
L5NARRATIVE_REVIEWCited in: Adjuvant and Palliative RT
[68]
Datta J, McMillan MT, Shang EK et al.. “Omission of adjuvant therapy after gastric cancer resection: development of a validated risk model.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25964639 ↗
L5OTHERCited in: Adjuvant and Palliative RT
[69]
Dikken JL, Jansen EP, Cats A et al.. “Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20368551 ↗
L4PHASE_1_TRIALCited in: Adjuvant and Palliative RT
[70]
Ghiglieri C, Dempster M, Wright S et al.. “Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review.” BMC palliative care (2023). PMID: 37891568 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT
[71]
Hong J, Chen Y, Li J et al.. “Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction: An updated Systematic Review and Meta-analysis.” American journal of surgery (2021). PMID: 34728070 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT
[72]
Guchelaar NAD, Nasserinejad K, Mostert B et al.. “Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis.” The British journal of surgery (2024). PMID: 38722803 ↗
L1SR_MA_RCTCited in: Adjuvant and Palliative RT
[73]
Wang Z, Dong L, Shi W et al.. “Postoperative therapy for local-advanced gastric cancer: A systematic review and meta-analysis.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2024). PMID: 38085005 ↗
L1SR_MA_RCTCited in: Adjuvant and Palliative RT
[74]
Orditura M, Martinelli E, Galizia G et al.. “Chemoradiotherapy as adjuvant treatment of gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591807 ↗
L5NARRATIVE_REVIEWCited in: Adjuvant and Palliative RT
[75]
Luo D, Xu H, Jiang C et al.. “The prognostic role of palliative gastrectomy in advanced gastric cancer: a systematic review and meta-analysis.” BMC cancer (2024). PMID: 39227821 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT
[76]
Kopecky K, Monton O, Rosman L et al.. “Palliative interventions for patients with advanced gastric cancer: a systematic review.” Chinese clinical oncology (2022). PMID: 36632980 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT
[77]
Meyer HJ, Wienke A, Surov A. “Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.” Nutrition and cancer (2022). PMID: 35603926 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT
[78]
Lee J, Lee J, Tripathi R et al.. “Sociodemographic Disparities and Impact of Palliative Care Utilization During End-of-Life Hospitalizations in Patients with Gastric Cancer.” Journal of palliative medicine (2025). PMID: 41466501 ↗
L3RETROSPECTIVE_COHORTCited in: Adjuvant and Palliative RT
[79]
Kim WJ, Choi CW, Kim SJ et al.. “Predictors of clinical failure after stenting for malignant esophageal stricture: a single-institution retrospective analysis.” Surgical endoscopy (2025). PMID: 40835762 ↗
L3COHORTCited in: Adjuvant and Palliative RT
[80]
Kitti P, Anttonen A, Nuutinen M et al.. “Specialist palliative care is associated with reduced healthcare utilization in patients with advanced esophageal and gastric cancer: a nationwide register-based study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40471285 ↗
L3RETROSPECTIVE_COHORTCited in: Adjuvant and Palliative RT
[81]
Jiang W, Wang H, Zhang X et al.. “Patterns of Recurrence After D2 Radical Surgery for Gastric Cancer: Implications for Postoperative Radiation Therapy.” Practical radiation oncology (2025). PMID: 40113039 ↗
L3COHORTCited in: Adjuvant and Palliative RT
[82]
Kim JW, Choi JY, Park W et al.. “Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital.” Cancer research and treatment (2025). PMID: 40083083 ↗
L4COHORTCited in: Adjuvant and Palliative RT
[83]
Santoni M, Guerra F, Conti A et al.. “Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.” Cancer treatment reviews (2017). PMID: 28818671 ↗
L2SR_COHORTCited in: Acute and Late Toxicity
[84]
Sasako M, Sano T, Yamamoto S et al.. “D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.” The New England journal of medicine (2008). PMID: 18669424 ↗
L1RCTCited in: Acute and Late Toxicity
[85]
Wang X, Zhang H, Xue Y et al.. “Comparing safety and short-term outcomes of proximal gastrectomy with double-flap technique and other reconstructions for proximal gastric cancer: a systematic review and meta-analysis.” BMC surgery (2026). PMID: 41580732 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity
[86]
Chen J, Wang F, Wang Y et al.. “A comparison of postoperative outcomes between robotic-assisted and laparoscopic-assisted total gastrectomy: a comprehensive meta-analysis and systematic review.” BMC surgery (2025). PMID: 40375289 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity
[87]
Zhu G, Jiao X, Zhou S et al.. “Can proximal gastrectomy with double-tract reconstruction replace total gastrectomy? a meta-analysis of randomized controlled trials and propensity score-matched studies.” BMC gastroenterology (2024). PMID: 39044132 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity
[88]
Menegat BLRS, Menegat ALRS, Dantas CR et al.. “Safety and feasibility of subtotal gastrectomy compared with completion total gastrectomy for remnant gastric cancer: A systematic review and meta-analysis.” Surgical oncology (2026). PMID: 42248045 ↗
L4SR_COHORTCited in: Acute and Late Toxicity
[89]
Miki Y, Bito T, Makuuchi R et al.. “Limited lymphadenectomy for elderly patient with gastric cancer: a systematic review and meta-analysis.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 41879959 ↗
L2SR_COHORTCited in: Acute and Late Toxicity
[90]
Chen M, Peng J, Lai H et al.. “Treatment of Gastric Cancer: Laparoscopic Pylorus-Preserving Gastrectomy or Laparoscopic Distal Gastrectomy? A Systematic Review and Meta-Analysis.” Journal of surgical oncology (2025). PMID: 41472564 ↗
L2SR_COHORTCited in: Acute and Late Toxicity
[91]
Zizzo M, Morini A, Zanelli M et al.. “Impact of Duodenal Stump Reinforcement in Preventing Duodenal Stump Fistula/Leakage After Distal or Total Gastrectomy for Malignant Disease: A Meta-Analysis of Comparative Studies.” Cancers (2025). PMID: 40507217 ↗
L2SR_COHORTCited in: Acute and Late Toxicity
[92]
Zaman S, Hussain MI, Kausar M et al.. “Intracorporeal versus extracorporeal anastomosis in laparoscopic total gastrectomy: a systematic review and meta-analysis.” International journal of surgery (London, England) (2025). PMID: 40009559 ↗
L2SR_COHORTCited in: Acute and Late Toxicity
[93]
Menegat ALRS, Menegat BLRS, Simões BCG et al.. “Comparative Outcomes of Spleen Preservation and Splenectomy in Total Gastrectomy for Proximal Gastric Cancer: A Systematic Review and Meta-Analysis.” Journal of gastrointestinal cancer (2025). PMID: 41091291 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity
[94]
Matsumoto Y, Terashima M, Fujiya K et al.. “Association between the inflow pattern of the left gastric vein and postoperative pancreatic fistula after laparoscopic gastrectomy.” Surgical endoscopy (2026). PMID: 42265294 ↗
L4COHORTCited in: Acute and Late Toxicity
[95]
Fujita S, Harada H, Okuno K et al.. “Pancreas-contactless open gastrectomy for gastric cancer and postoperative pancreatic complications: A retrospective cohort study.” Surgical oncology (2026). PMID: 42250430 ↗
L3RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity
[96]
Takahashi K, Fujiya K, Terashima M et al.. “Comparison of long-term outcomes of robotic gastrectomy and laparoscopic gastrectomy using the modified age-adjusted Charlson Comorbidity Index.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42113328 ↗
L3COHORTCited in: Acute and Late Toxicity
[97]
Filip B, Grigoraș A, Scripcariu DV et al.. “Neoadjuvant Treatment Versus Upfront Surgery in Gastric Cancer Patients: Early Postoperative and Pathological Results: A Retrospective Study in a Tertiary Center.” Journal of clinical medicine (2026). PMID: 41899266 ↗
L4COHORTCited in: Acute and Late Toxicity
[98]
Tokuhara T, Nakata E, Kawai I et al.. “Reframing gastric lymph nodes as a parapancreatic lymph chain: an embryology-driven rationale for omento-bursectomy and omentum-preserving gastrectomy to facilitate safe infrapyloric lymph node dissection.” World journal of surgical oncology (2025). PMID: 41470024 ↗
L3RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity
[99]
Ri M, Nunobe S, Narita T et al.. “Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning: a multicenter cohort study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2025). PMID: 40921854 ↗
L3COHORTCited in: Acute and Late Toxicity
[100]
Yamaguchi T, Kadoya S, Ishibayashi K et al.. “Asthma is a risk factor for postoperative pulmonary complications and intra-abdominal infectious complications after gastrectomy.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2025). PMID: 40744154 ↗
L3COHORTCited in: Acute and Late Toxicity
[101]
Huang J, Dong Z, Chen F et al.. “Risk analysis of jejunal orientation on the incidence of dysphagia after total gastrectomy: a retrospective cohort study.” Surgical endoscopy (2025). PMID: 40116901 ↗
L4RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity
[102]
Ushimaru Y, Omori T, Yamamoto K et al.. “Robotic and laparoscopic gastrectomy for gastric cancer: comparative insights into perioperative performance and three-year survival outcomes.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2025). PMID: 40009253 ↗
L3RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity
[103]
Nitti D, Wils J, Dos Santos JG et al.. “Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16293676 ↗
L1SR_MA_RCTCited in: Outcomes
[104]
Sada YH, Smaglo BG, Tan JC et al.. “Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787129 ↗
L3RETROSPECTIVE_COHORTCited in: Outcomes
[105]
Singh PP, Singh S. “Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23599253 ↗
L2SR_COHORTCited in: Outcomes
[106]
Okines AFC, Norman AR, McCloud P et al.. “Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19474114 ↗
L2SR_COHORTCited in: Outcomes
[107]
Cassidy J, Saltz L, Twelves C et al.. “Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21415237 ↗
L2SR_COHORTCited in: Outcomes
[108]
Pietrantonio F, Randon G, Di Bartolomeo M et al.. “Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.” ESMO open (2021). PMID: 33460964 ↗
L1SR_MA_RCTCited in: Outcomes
[109]
Janjigian YY, Shitara K, Ajani JA et al.. “Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41687718 ↗
L1RCTCited in: Outcomes
[110]
Park SH, Lim DH, Sohn TS et al.. “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33278599 ↗
L1RCTCited in: Outcomes
[111]
Liu R, Zhao J, Zhang R et al.. “Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41571045 ↗
L1RCTCited in: Outcomes
[112]
Wang X, Jiang Y, Yang S et al.. “Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40168636 ↗
L2PROSPECTIVE_COHORTCited in: Outcomes
[113]
Shen L, Shan YS, Hu HM et al.. “Management of gastric cancer in Asia: resource-stratified guidelines.” The Lancet. Oncology (2013). PMID: 24176572 ↗
L1GUIDELINECited in: Outcomes
[114]
Kang YK, Yook JH, Park YK et al.. “PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34133211 ↗
L1RCTCited in: Outcomes
[115]
Sakai D, Kadowaki S, Kawabata R et al.. “Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40408613 ↗
L1RCTCited in: Outcomes
[116]
Li C, Tian Y, Zheng Y et al.. “Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39383487 ↗
L1RCTCited in: Outcomes
[117]
van der Veen A, Brenkman HJF, Seesing MFJ et al.. “Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34581617 ↗
L1RCTCited in: Outcomes
[118]
Li J, Qin S, Xu J et al.. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26884585 ↗
L1RCTCited in: Outcomes
[119]
Lee CK, Kim HS, Jung M et al.. “Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37883723 ↗
L1RCTCited in: Outcomes
[120]
Hu Y, Huang C, Sun Y et al.. “Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26903580 ↗
L1RCTCited in: Outcomes